SEMA7A and adrenal cortex carcinoma: These results suggest that ACC tumors with high SEMA7A expression should be considered at elevated risk, and SEMA7A may serve as a potential target for immunotherapeutic strategies, including antibody–drug conjugates, T-cell engagers, and/or small-molecule inhibitors targeting the MAPK pathway.